08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral...
07:00 , Oct 10, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Focusing the BRAIN The NIH 's BRAIN initiative has developed a road map for its near-term research priorities, chief among which is conducting a census of brain cells. Whether the ambitious, decades-long project will be...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Anida, ALS Therapy Development Institute (ALS TDI) deal

The not-for-profit partnered with Anida to evaluate Anida's preclinical compound, neuroprotectin D1 ( NPD1 ), in superoxide dismutase 1 (SOD1) mice as a potential treatment for amyotrophic lateral sclerosis (ALS). ALS TDI said it will...